Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.

Slaughter, Katrina N

Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. [electronic resource] - Gynecologic oncology Apr 2014 - 11-5 p. digital

Publication Type: Comparative Study; Journal Article; Observational Study

1095-6859

10.1016/j.ygyno.2014.01.031 doi


Adiposity
Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab
Body Mass Index
Carboplatin--administration & dosage
Carcinoma, Ovarian Epithelial
Female
Humans
Intra-Abdominal Fat--diagnostic imaging
Middle Aged
Multivariate Analysis
Neoplasms, Glandular and Epithelial--blood
Obesity--blood
Ovarian Neoplasms--blood
Overweight--blood
Paclitaxel--administration & dosage
Pilot Projects
Prognosis
Proportional Hazards Models
Retrospective Studies
Subcutaneous Fat--diagnostic imaging
Tomography, X-Ray Computed
Treatment Outcome
Vascular Endothelial Growth Factor A--blood